Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation

Chimeric antigen receptor T-cells (CART) are active in relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), but relapse remains a substantial challenge. Reinfusion with the same CART product (CART2) in patients with suboptimal response or antigen positive relapse following first in...

Descripción completa

Detalles Bibliográficos
Autores principales: Holland, Elizabeth M, Molina, John C, Dede, Kniya, Moyer, Daniel, Zhou, Ting, Yuan, Constance M, Wang, Hao-Wei, Stetler-Stevenson, Maryalice, Mackall, Crystal, Fry, Terry J, Panch, Sandhya, Highfill, Steven, Stroncek, David, Little, Lauren, Lee, Daniel W, Shalabi, Haneen, Yates, Bonnie, Shah, Nirali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086629/
https://www.ncbi.nlm.nih.gov/pubmed/35534047
http://dx.doi.org/10.1136/jitc-2021-004483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086629/
https://www.ncbi.nlm.nih.gov/pubmed/35534047
http://dx.doi.org/10.1136/jitc-2021-004483

Ejemplares similares